US Patent and Trademark Office Publishes BetterLife’s Comprehensive Patent for BETR-001 and Other LSD Derivatives
15 Noviembre 2023 - 7:00AM
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR
/ OTCQB: BETRF / FRA: NPAU), an emerging biotech company
focused on the development and commercialization of cutting-edge
treatments for mental disorders, is pleased to announce that its
patent application for BETR-001 and LSD derivatives titled “LSD
derivatives, synthesis & method for treatment of diseases and
disorders” has been published by the United States Patent and
Trademark Office (“USPTO”) under publication number
US-2023/0357243-A1 and available for access on USPTO’s databases.
BetterLife is presently developing one of these derivatives: a
2-bromo derivative of LSD (BETR-001) that is non-hallucinogenic
and, in preclinical animal models, has been shown to be a potent
neuroplastogen and have efficacy against depression/anxiety states.
This published U.S. patent is part of a
developing international patent portfolio which cover new
compositions of 2-bromo-LSD and other LSD derivatives. In addition
to composition claims, these applications also cover a novel method
for making non-hallucinogenic LSD derivatives that does not involve
the use of controlled substances at any stage. The applications
also cover use of these derivatives in the treatment of a range of
neuropsychiatric and neurological conditions, including depression,
anxiety, cluster headaches and neuropathic pain.
Betterlife is also pleased that its efforts to
develop novel therapies for mental disorders were highlighted in
the November 8 edition of The Atlantic. The Atlantic journal
highlighted the potential of the BETR-001 program, as a
non-hallucinogenic analog of LSD, in an article entitled “What If
Psychedelics’ Hallucinations Are Just a Side Effect?” The article
discusses, in part, that a growing number of key opinion leaders in
neuroscience now believe that the hallucination caused by
psychedelics is just a side effect and not necessary to produce
mental-health benefits by this class of drugs. BETR-001 is
currently undergoing IND-enabling studies and projected to enter
human trials in 2024.
Dr. Ahmad Doroudian, CEO of BetterLife
commented, “We are very pleased with the recognition of our
development work in The Atlantic as well as the publication of our
patent. These strong claims on synthesis and composition of
BETR-001, including its stereoisomers and polymorphs, will greatly
enhance the value of our lead product, much like we are seeing with
similar composition patents for molecules such as S-and R-ketamine
and psilocybin polymorphs that have recently been upheld by the
USPTO.”
About BetterLife Pharma
BetterLife Pharma Inc. is an emerging
biotechnology company primarily focused on developing and
commercializing two compounds, BETR-001 and BETR-002, to treat
neuro-psychiatric and neurological disorders.
BETR-001, which is in preclinical and
IND-enabling studies, is a non-hallucinogenic and non-controlled
LSD derivative in development and it is unique in that it is
unregulated and therefore can be self-administered. BetterLife’s
synthesis patent for BETR-001 eliminates regulatory hurdles and its
pending patent, for composition and method of use, covers treatment
of major depressive disorder, anxiety disorder and neuropathic pain
and other neuro-psychiatric and neurological disorders.
BETR-002, which is in preclinical and
IND-enabling studies, is based on honokiol, the active anxiolytic
ingredient of magnolia bark. BetterLife’s pending method of use and
formulations patent covers treatment of anxiety related disorders
including benzodiazepine dependency.
BetterLife also owns a drug candidate for the
treatment of viral infections such as COVID-19 and is in the
process of seeking strategic alternatives for further
development.
For further information, please
visit BetterLife Pharma.
BetterLife Pharma Inc. Contact
Information
David Melles, Investor Relations ManagerEmail:
David.Melles@blifepharma.comPhone: 1-778-887-1928
Cautionary Note Regarding
Forward-Looking Statements
No securities exchange has reviewed nor accepts
responsibility for the adequacy or accuracy of the content of this
news release. This news release contains forward-looking statements
relating to product development, licensing, commercialization and
regulatory compliance issues and other statements that are not
historical facts. Forward-looking statements are often identified
by terms such as “will”, “may”, “should”, “anticipate”, “expects”
and similar expressions. All statements other than statements of
historical fact, included in this release are forward-looking
statements that involve risks and uncertainties. There can be no
assurance that such statements will prove to be accurate and actual
results and future events could differ materially from those
anticipated in such statements. Important factors that could cause
actual results to differ materially from the Company’s expectations
include the failure to satisfy the conditions of the relevant
securities exchange(s) and other risks detailed from time to time
in the filings made by the Company with securities regulations. The
reader is cautioned that assumptions used in the preparation of any
forward-looking information may prove to be incorrect. Events or
circumstances may cause actual results to differ materially from
those predicted, as a result of numerous known and unknown risks,
uncertainties, and other factors, many of which are beyond the
control of the Company. The reader is cautioned not to place undue
reliance on any forward-looking information. Such information,
although considered reasonable by management at the time of
preparation, may prove to be incorrect and actual results may
differ materially from those anticipated. Forward-looking
statements contained in this news release are expressly qualified
by this cautionary statement. The forward-looking statements
contained in this news release are made as of the date of this news
release and the Company will update or revise publicly any of the
included forward-looking statements as expressly required by
applicable law.
BetterLife Pharma (TG:NPAU)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
BetterLife Pharma (TG:NPAU)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024